Amgen Tour of California to include Thousand Oaks to Santa Barbara leg
Organizers of the 12th annual Amgen Tour of California bicycle race announced the full route on Jan. 28. The 2016 race will run 782.7 miles from San Diego to Sacramento from May 15 to May 22. This year will also be just the second time out of 11 previous races that the route runs south Read More →
Amgen revenues up 8 percent in 2015
Despite increased competition from biosimilars and blockbuster mergers by its rivals, Amgen revenues rose 8 percent to $21.67 billion in 2015 from $20.06 billion in 2014. Thousand Oaks-based biotech giant Amgen released its fourth-quarter earnings after markets closed on Jan. 28. Quarterly revenues were also up 4 percent to $5.54 billion in 2015 from $5.33 Read More →
Tri-Counties race to control marijuana
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen drug Kyprolis gets another FDA approval
Amgen scored another victory for its breakthrough multiple myeloma drug on Jan. 21. The Thousand Oaks-based biotech giant hit it big when the Food and Drug Administration approved revolutionary multiple myeloma drug Kyprolis for treatments with Kyprolis in combination with another drug. The FDA also approved Kyprolis to treat patients on its own for those Read More →
Shire buying Conejo Valley’s Baxalta
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen suffers setback as patent office refuses to review competitor’s drug
The U.S. Patent and Trademark Office handed Amgen a potential setback Jan. 14 when it declined to review two patent expiration dates on a competitor’s drug. In June, Thousand Oaks-based biotech giant Amgen asked the agency to review two formulation patents for Humira, made by Chicago-based competitor AbbVie, arguing that the patents should not have Read More →
Shire acquiring Baxalta for $32 billion
Shire PLC sweetened the pot and Baxalta Inc. investors took the bait in a deal announced early Jan. 11. Dublin-based Shire announced a $30 billion bid for Deefield, Ill.-based Baxalta on Aug. 4. On Jan. 11, the companies announced Shire will acquire Baxalta for $32 billion. Baxalta employs about 2,000 people in Thousand Oaks and Read More →
